Due to concerns about the current therapeutic modalities for Helicobacter pylori infection, e.g., the increased emergence of drug-resistant strains and the adverse reactions of drugs currently administered, there is a need to develop an anti-H. pylori agent with higher efficacy and less toxicity. The antibacterial activity of TG44, an anti-H. pylori agent with a novel structural formula, against 54 clinical isolates of H. pylori was examined and compared with those of amoxicillin (AMX), clarithromycin (CLR), and metronidazole (MNZ). Consequently, TG44 inhibited the growth of H. pylori in an MIC range of 0.0625 to 1 g/ml. The MIC ranges of AMX, CLR, and MNZ were 0.0078 to 8 g/ml, 0.0156 to 64 g/ml, and 2 to 128 g/ml, respectively. The antibacterial activity of TG44 against AMX-, CLR-, and MNZ-resistant strains was nearly comparable to that against drug-susceptible ones. In a pH range of 3 to 7, TG44 at 3.13 to 12.5 g/ml exhibited potent bactericidal activity against H. pylori in the stationary phase of growth as early as 1 h after treatment began, in contrast to AMX, which showed no bactericidal activity at concentrations of up to 50 g/ml at the same time point of treatment. TG44 at 25 g/ml exhibited no antibacterial activity against 13 strains of aerobic bacteria, suggesting that its antibacterial activity against H. pylori is potent and highly specific. The present study indicated that TG44 possesses antibacterial activity which manifests quickly and is potentially useful for eradicating not only the antibiotic-susceptible but also the antibioticresistant strains of H. pylori by monotherapy.
We previously conducted an in vitro study of 4-amino-5-chloro-2-methoxy-N-(1-ethyl-2-hydroxymethyl-4-pyrrolidinyl)benzamide (2S,4S)-(1, TKS159) and its three optical isomers (2S,4R)-(2), (2R,4S)-(3) and (2R,4R)-(4) with respect to their binding ability to the 5-HT(4) receptors, as well as an in vivo study on their gastric emptying-accelerating ability in rats. Consequently, we reported that steric configuration at positions 2 and 4 of the pyrrolidine ring is important in determining their pharmacological activity. The optical isomer (2R,4S)-(3) exhibited the most potent binding ability. However, the compound (2S,4S)-(1, TKS159) exhibited the most potent gastric emptying-accelerating ability in rats. A difference was thus found between binding ability and gastric emptying-accelerating ability in rats. Therefore, we conducted an in vitro study of TKS159 (1) and its three optical isomers to examine their agonistic activity on the 5-HT(4) receptors, as well as an in vivo study in mice to examine their gastric emptying-accelerating ability. Consequently, a tendency for correlation was found between the activity and the ability. TKS159 (1) exhibited the most potent pharmacological activity, well reflecting the results from the previous in vivo study in rats. Furthermore, the present in vitro and in vivo studies reverified the importance of steric configuration at positions 2 and 4 of the pyrrolidine ring. In addition, we also made an X-ray crystallographic analysis of the optical isomer (2R,4S)-(3), which has the S-configuration at position 4 similar to TKS159 (1), and discussed molecular structures in conjunction with the previously reported results from the X-ray crystallographic analysis of TKS159 (1).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.